Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs

Sunovion, owned by Japan’s Sumitomo Dainippon Pharma, has signed a near $1 billion upfront/biobucks mix deal with fellow Japanese native Otsuka Pharmaceutical.